Jennifer Salvitti Davis, M.D Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 750 E Beau St, Washington, PA 15301 Phone: 724-228-2982 Fax: 724-228-8117 |
Ernest Ronald Salvitti, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 750 E Beau St, Washington, PA 15301 Phone: 724-228-2982 Fax: 724-228-8117 |
Sean F Pieramici, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 750 E Beau St, Washington, PA 15301 Phone: 724-228-2982 Fax: 724-228-8117 |
Frederick J Scheib, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 212 Wilson Ave, Washington, PA 15301 Phone: 724-223-0700 Fax: 724-229-8680 |
Dr. Paul E. Caimano, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2107 North Franklin Dr., Suite 1, Washington, PA 15301 Phone: 724-222-3937 Fax: 724-222-7570 |
News Archive
Columbia University Medical Center (CUMC) scientists have demonstrated that two related enzymes - phosphoinositide-3 kinase (PI3K) gamma and delta - play a key role in the development of T-cell acute lymphoblastic leukemia (T-ALL), a highly aggressive childhood leukemia that is difficult to treat.
Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled "Therapeutic Effectiveness of T-Cell Receptor mimic (TCRmâ„¢) Antibodies in Breast Cancer Treatment" will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies.
With more oil from the BP spill in the Gulf washing ashore, regional communities will have a huge job of cleaning up after this vast environmental disaster. As kind-hearted volunteers participate in the effort to save both wildlife and the local environment, they will be putting themselves at risk of long-term health effects.
Experiments in mice with a bone disorder similar to that in women after menopause show that a scientifically overlooked group of cells are likely crucial to the process of bone loss caused by the disorder, according to Johns Hopkins researchers.
Dutch investigators have reported that women who received CMF chemotherapy (a combination regimen including the drugs cyclophosphamide, methotrexate, and 5-fluorouracil) for breast cancer between 1976 and 1995 scored worse on cognitive tests than women who never had cancer.
› Verified 9 days ago